Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Crism Thera (CRTX) Share Price

Price 12.75p on 06-02-2026 at 19:10:06
Change -0.25p -1.92%
Buy 13.50p
Sell 12.00p
Last Trade: Buy 20,000.00 at 13.199p
Day's Volume: 73,187
Last Close: 12.75p
Open: 12.75p
ISIN: VGG042401262
Day's Range 12.75p - 12.75p
52wk Range: 6.25p - 29.00p
Market Capitalisation: £6.60m
VWAP: 13.14106p
Shares in Issue: 51.74m

Crism Thera (CRTX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 20,000 13.199p Ordinary
16:22:02 - 06-Feb-26
Buy* 2 13.50p Ordinary
16:04:12 - 06-Feb-26
Buy* 1,130 13.27p Ordinary
15:54:35 - 06-Feb-26
Buy* 6 13.50p Ordinary
15:05:03 - 06-Feb-26
Buy* 37 13.50p Ordinary
15:00:58 - 06-Feb-26
Buy* 5,666 13.50p Ordinary
14:42:51 - 06-Feb-26
Sell* 1,483 12.70p Ordinary
13:57:19 - 06-Feb-26
Buy* 7,380 13.199p Ordinary
13:57:01 - 06-Feb-26
Buy* 140 13.50p SI Trade
12:53:43 - 06-Feb-26
Sell* 111 12.00p SI Trade
12:53:43 - 06-Feb-26
See more Crism Thera trades

Crism Thera (CRTX) Share Price History

Time period:
to
Date Open High Low Close Volume
6th Feb 2026 (Fri) 12.75 12.75 12.75 12.75 73,187
5th Feb 2026 (Thu) 13.00 13.00 13.00 13.00 1,098,322
4th Feb 2026 (Wed) 13.00 13.00 13.00 13.00 235,932
3rd Feb 2026 (Tue) 12.50 13.00 12.50 13.00 498,857
2nd Feb 2026 (Mon) 10.25 13.50 11.00 12.50 1,566,789
30th Jan 2026 (Fri) 10.25 10.25 10.25 10.25 369,252
29th Jan 2026 (Thu) 10.25 10.25 10.25 10.25 202,278
28th Jan 2026 (Wed) 10.25 10.25 10.25 10.25 21,714
27th Jan 2026 (Tue) 10.25 10.25 10.25 10.25 685,275
26th Jan 2026 (Mon) 10.25 10.25 10.25 10.25 283,811
23rd Jan 2026 (Fri) 10.25 10.25 10.25 10.25 66,297
22nd Jan 2026 (Thu) 10.25 10.25 10.25 10.25 238,481
21st Jan 2026 (Wed) 10.25 10.25 10.25 10.25 106,205
20th Jan 2026 (Tue) 10.25 10.25 10.25 10.25 183,396
19th Jan 2026 (Mon) 10.00 10.00 10.00 10.00 764,315
16th Jan 2026 (Fri) 9.75 10.00 9.75 10.00 652,836
15th Jan 2026 (Thu) 10.50 10.50 9.75 9.75 45,233
14th Jan 2026 (Wed) 10.50 10.50 10.50 10.50 12,065
13th Jan 2026 (Tue) 10.50 10.50 10.50 10.50 325,105
12th Jan 2026 (Mon) 10.75 10.75 10.50 10.50 39,925
9th Jan 2026 (Fri) 10.75 10.75 10.75 10.75 34,587
8th Jan 2026 (Thu) 10.75 10.75 10.75 10.75 96,316
7th Jan 2026 (Wed) 10.75 10.75 10.75 10.75 8,982
See more Crism Thera price history

Crism Thera (CRTX) Regulatory News

Date Source Headline
20th Jan 2026 7:00 am RNS Japanese Patent Grant
9th Jan 2026 7:00 am RNS Results of Shareholder Analysis
15th Dec 2025 2:29 pm RNS Result of Retail Offer
10th Dec 2025 7:25 am RNS Retail Offer
10th Dec 2025 7:00 am RNS Placing of £1,000,000
27th Nov 2025 7:00 am RNS Holding(s) in Company
30th Oct 2025 7:00 am RNS US Orphan Drug Designation Application
14th Oct 2025 7:00 am RNS Positive Preclinical Data in Prostate Cancer
15th Sep 2025 7:00 am RNS Half Year Report
12th Sep 2025 7:00 am RNS Notice of Interim Results and IMC Presentation
See more Crism Thera regulatory news

Crism Thera (CRTX) Share News

TRADING UPDATES: Netcall acquires Jadu for up to GBP19 million

10th Dec 2025 16:16

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

CRISM reports "significant" preclinical data for prostate cancer drug

14th Oct 2025 16:50

(Alliance News) - CRISM Therapeutics Corp said on Tuesday that preclinical studies show that its ChemoSeed drug delivery platform could "could substantially enhance" the efficacy of docetaxel in the treatment of prostate cancer. Read More

EARNINGS: CRISM loss widens as "actively" prepares for phase 2 trial

15th Sep 2025 21:41

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: CRISM confident in ChemoSeed as targets trial approval

26th Aug 2025 13:56

CRISM Therapeutics Corp - British Virgin Islands-based pharmaceutical firm - As the firm held its annual general meeting, Chair Nermeen Varawalla says the firm must attract, retain and incentivise the best people as it continues to seek further validation for its novel delivery method. "[We] are confident that ChemoSeed has the potential to transform treatment for patients with solid-tumour cancers," Chair Varawalla continues. ChemoSeed is an implantable biodegradable drug delivery technology designed for the sustained delivery of chemotherapy directly into cancer tissue. Chair Varawalla says the company is focused on gaining trial approval from the UK Medicines & Healthcare products Regulatory Agency in glioblastoma and progressing towards dosing first patients in early 2026. Read More

UK shareholder meetings calendar - next 7 days

19th Aug 2025 14:58

Read More

See more Crism Thera news
FTSE 100 Latest
Value10,369.75
Change60.53

Login to your account

Forgot Password?

Not Registered